Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
P H ChandrasekarE K Manavathu

Abstract

The efficacy of voriconazole in combination with amphotericin B or micafungin was studied in a transiently neutropenic guinea-pig model of invasive pulmonary aspergillosis. Guinea-pigs treated with the antifungal drugs, alone or in two-drug combinations, had an improved survival rate and reduced fungal burden in the lungs compared to untreated control animals. The efficacy of monotherapy and combination therapy was similar; activity was neither enhanced nor reduced with the two-drug combinations. Further studies of efficacy, dosing and optimal regimens for antifungal combinations are warranted.

References

May 1, 1985·The Journal of Infectious Diseases·A Schaffner, P G Frick
Jun 13, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D W Denning
May 8, 2000·The Journal of Antimicrobial Chemotherapy·P H ChandrasekarE Manavathu
Aug 7, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M M McNeilD W Warnock
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·William R KirkpatrickThomas F Patterson
Aug 9, 2002·The New England Journal of Medicine·Raoul HerbrechtUNKNOWN Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillu

❮ Previous
Next ❯

Citations

Apr 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P H Chandrasekar, J D Sobel
May 10, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose A Vazquez
Nov 24, 2005·Antimicrobial Agents and Chemotherapy·Kathrin HeynFrank-Michael C Müller
Jan 3, 2006·American Journal of Respiratory and Critical Care Medicine·Brahm H Segal, Thomas J Walsh
Jul 14, 2011·Clinical Epidemiology·Jane KriengkauykiatSanjeet S Dadwal
Mar 25, 2008·Therapeutics and Clinical Risk Management·Javier PemánMiguel Gobernado
Jul 31, 2007·Future Microbiology·Jörg J Vehreschild, Oliver A Cornely
Jul 31, 2007·Future Microbiology·Jose A Vazquez
Oct 5, 2007·Expert Review of Anti-infective Therapy·Brahm H Segal, William J Steinbach
Oct 7, 2005·Expert Review of Anti-infective Therapy·Livio PaganoLuana Fianchi
Aug 7, 2009·Expert Opinion on Investigational Drugs·Susanne Perkhofer, Cornelia Lass-Flörl
Apr 1, 2011·Enfermedades infecciosas y microbiología clínica·Isabel Ruiz-Camps
Dec 29, 2006·Pharmacotherapy·Jomy M JosephLarry H Danziger
Jan 15, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·N SinghJ Levitsky
Feb 18, 2010·Pediatrics International : Official Journal of the Japan Pediatric Society·Takaaki OkamotoKohmei Ida
May 17, 2015·International Journal of Antimicrobial Agents·Ranjith RajendranGordon Ramage
Jun 17, 2005·Expert Opinion on Pharmacotherapy·Grzegorz Kofla, Markus Ruhnke
Feb 1, 2014·The Journal of Infection·D A EnochJ A Karas
Apr 24, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J P Adler-Moore, R T Proffitt
Jun 29, 2006·Current Opinion in Infectious Diseases·Helen L Leather, John R Wingard
Jun 29, 2010·Pediatric Hematology and Oncology·Fatma Betul CakirElif Dagli
Jun 1, 2017·Frontiers in Microbiology·Guillaume Desoubeaux, Carolyn Cray

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.